Literature DB >> 11950426

Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris.

Hans Martin Hoffmeister1, Raila Ehlers, Evi Büttcher, Silke Kazmaier, Sebastian Szabo, Martin E Beyer, Armin Steinmetz, Ludger Seipel.   

Abstract

Elevated C-reactive protein (CRP) can identify patients with coronary artery disease who are prone to future acute events. We investigated whether elevated CRP is related to the activation of the terminal complement cascade in 66 patients with unstable angina pectoris (UAP), in 45 patients with stable angina pectoris, and in 42 controls. CRP, additional acute phase reactants, the terminal complement complex (sC5b-9), leukocytes, and troponin T were measured. In 47 patients with UAP the CRP values were regarded as elevated (>0.3 mg/dl). In patients with UAP and elevated CRP, the plasma levels of sC5b-9 were markedly higher than in patients with UAP and lower CRP (245 +/- 14 vs 188 +/- 19 ng/ml, p <0.02) and in patients with stable angina pectoris with slightly (0.4 +/- 0.1 mg/dl) increased CRP (sC5b-9 173 +/- 21 vs 130 +/- 7 ng/ml [controls; p <0.05]). A further acute phase reaction was present only in patients with UAP and elevated CRP already on admission (p <0.01). sC5b-9 was not related to troponin release. Thus, elevated CRP levels are associated with activation of the plaque destabilizating terminal complement system in patients with UAP during the acute phase reaction. This may explain the prognostic value of CRP in acute coronary syndromes (ACS).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950426     DOI: 10.1016/s0002-9149(02)02237-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Plasma Complement Protein C3a Level Was Associated with Abdominal Aortic Calcification in Patients on Hemodialysis.

Authors:  Yaqin Wang; Yuanyi Miao; Kunjing Gong; Xuyang Cheng; Yuqing Chen; Ming-Hui Zhao
Journal:  J Cardiovasc Transl Res       Date:  2019-04-15       Impact factor: 4.132

Review 2.  Complement activity and pharmacological inhibition in cardiovascular disease.

Authors:  Pierre Théroux; Catherine Martel
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

3.  Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS).

Authors:  C H Lee; P de Feyter; P W Serruys; F Saia; P A Lemos; D Goedhart; P R Soares; V A W M Umans; M Ciccone; M Cortellaro
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

4.  Complement component 7 is associated with total- and cardiac death in chest-pain patients with suspected acute coronary syndrome.

Authors:  Reidun Aarsetøy; Thor Ueland; Pål Aukrust; Annika E Michelsen; Ricardo Leon de la Fuente; Heidi Grundt; Harry Staines; Ottar Nygaard; Dennis W T Nilsen
Journal:  BMC Cardiovasc Disord       Date:  2021-10-14       Impact factor: 2.298

5.  Cardioembolic and small vessel disease stroke show differences in associations between systemic C3 levels and outcome.

Authors:  Anna Stokowska; Sandra Olsson; Lukas Holmegaard; Katarina Jood; Christian Blomstrand; Christina Jern; Marcela Pekna
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

Review 6.  Structural and functional diversity of collectins and ficolins and their relationship to disease.

Authors:  Mark Howard; Conrad A Farrar; Steven H Sacks
Journal:  Semin Immunopathol       Date:  2017-09-11       Impact factor: 9.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.